Filtered By:
Source: Heart Rhythm
Drug: Warfarin
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration
The effect of uninterrupted oral anticoagulant use in patients with chronic kidney disease (CKD) during catheter ablation for atrial fibrillation (AF) is not fully understood.
Source: Heart Rhythm - October 26, 2017 Category: Cardiology Authors: Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, Monami Ando, Junya Funabiki, Yosuke Murase, Masaki Takenaka, Noriaki Otake, Yoshihiro Ikai, Yusuke Sakamoto, Rei Shibata, Toyoaki Murohara Source Type: research
Left Atrial Appendage Closure Device Implantation in Patients with Atrial Fibrillation and Prior Intracranial Hemorrhage “No Man Left Behind”
Several LAA closure devices have been developed for patients with atrial fibrillation (AF) seeking an alternative to long-term oral anticoagulation (OAC). The PROTECT AF trial was the first multicenter randomized controlled trial (RCT) comparing LAA closure device vs. OAC with Warfarin. Primary safety events were statistically more frequent in the device group (7.4% vs. 4.4%). At a mean follow up of 3.8 years LAA closure device showed superiority for the primary efficacy endpoint (i.e., composite of stroke, cardiovascular death and systemic embolism), with a 34% relative risk reduction in total mortality1-3 However, with t...
Source: Heart Rhythm - January 14, 2019 Category: Cardiology Authors: Luigi Di Biase, Jorge Romero Source Type: research
EP News: Allied Professionals
Di Biase et al (J Am Coll Cardiol 2019;74:1019, PMID 31439209) sought to assess the incidence of thromboembolic (TE) events such as stroke and transient ischemic attack (TIA) in patients with atrial fibrillation (AF) undergoing ablation for AF that included left atrial appendage (LAA) isolation (LAAI). The st udy group comprised all patients who underwent LAAI as part of their ablation strategy and who were without AF 6 months after ablation. All patients were continued on oral anticoagulation (OAC) with either warfarin or direct oral anticoagulant (DOAC) for the first 6 months.
Source: Heart Rhythm - September 15, 2019 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research
Anticoagulation for Stroke Prevention in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review
Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy with a prevalence and incidence of 23% and 3.1% respectively. The risk of thromboembolism is high in patients with hypertrophic cardiomyopathy regardless of the CHADS2VASC score. This review includes five observational studies that focused on prevention of thromboembolism in patients with hypertrophic cardiomyopathy and atrial fibrillation. These papers evaluated and compared outcomes between patients on either warfarin or direct oral anticoagulants.
Source: Heart Rhythm - October 2, 2020 Category: Cardiology Authors: M. Farhan Nasser, Sanjay Gandhi, Robert J. Siegel, Florian Rader Source Type: research
B-po05-154 an updated meta-analysis comparing left atrial appendage closure and oral anticoagulation
Left atrial appendage closure (LAAC) trials such as PREVAIL and PROTECT revealed non-inferiority of LAAC compared to warfarin. The recently published PRAGUE study showed that LAAC was non-inferior to direct oral anti-coagulants. Current guidelines give a IIb recommendation for LAAC in patients with non-valvular atrial fibrillation (NVAF) with increased risk of stroke and contraindication to long-term anticoagulation.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Sisir Siddamsetti, Arshad Muhammad Iqbal, Alexander Shinn, Sandeep Gautam Source Type: research
B-po03-155 outcomes of left atrial appendage occlusion with watchman in contemporary clinical practice compared with clinical trials: a pooled analysis of protect-af, prevail, and the ncdr laao registry
The PROTECT-AF and PREVAIL trials established Watchman left atrial appendage occlusion (LAAO) as an alternative to warfarin for stroke protection in atrial fibrillation. In clinical practice, LAAO is often performed in patients who cannot tolerate long-term anticoagulation and have more cardiac and non-cardiac comorbidities.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Daniel J. Friedman, Chengan Du, Yongfei Wang Vratika Agarwal, Paul D. Varosy, Frederick A. Masoudi, Jeptha P. Curtis, James Freeman Source Type: research
